A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR)
Study identifier:4522IL/0088
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase III Study Measuring Effects on Intima Media Thickness: an Evaluation Of Rosuvastatin 40 mg (METEOR)
Medical condition
Hypercholesteremia
Phase
Phase 3
Healthy volunteers
No
Study drug
Rosuvastatin calcium
Sex
All
Actual Enrollment
840
Study type
Interventional
Age
45 Years - 70 Years
Date
Study Start Date: 01 Aug 2002
Primary Completion Date: 01 May 2006
Study Completion Date: 01 May 2006
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Other
Verification:
Verified 01 Nov 2010 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Location
Research Site
Brussels, Belgium
Location
Research Site
Brussels (Anderlecht), Belgium
Location
Research Site
Leuven, Belgium
Location
Research Site
Praha 2, Czech Republic
Location
Research Site
Kuopio, Finland
Location
Research Site
Bagnolet, France
Location
Research Site
BOULOGNE BILLANCOURT, France
Location
Research Site
BRIEY, France
| Arms | Assigned Interventions |
|---|
Contacts
Contact
AstraZeneca Information Center Telephone: 800-236-9933, (US - 8a-7p EST);
-
Investigators
Principal Investigator
AstraZeneca Crestor Medical Science Director
AstraZeneca
